A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.

Trial Profile

A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors TAP Pharmaceutical Products
  • Most Recent Events

    • 01 Nov 2009 Primary endpoint 'Disease recurrence rate' has been met.
    • 01 Nov 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
    • 01 Sep 2009 Actual patient number (451) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top